Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
27 participants
Jul 19, 2021
INTERVENTIONAL
Conditions
Summary
The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months). The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
Eligibility
Inclusion Criteria4
- Patients older than 18 years old
- Chronic rhinosinusitis with Nasal Polyps
- Olfactory loss
- Clinical indication for treatment with Dupilumab
Exclusion Criteria7
- Patients with olfactory loss from other causes such as:
- Sinonasal malignancies
- Trauma
- Idiopathic olfactory loss
- Use of cocaine
- COVID-19 related olfactory loss
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04869436